Breaking News, Collaborations & Alliances

BMS, WuXi PharmaTech in Shanghai Stability Pact

Bristol-Myers Squibb and WuXi PharmaTech have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and WuXi PharmaTech have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications. WuXi will build and operate a dedicated, 25,000-sq.-ft. cGMP analytical testing facility in Shanghai to store and test stability samples and perform other services for BMS. WuXi will also employ a staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, met...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters